Saving changes...



New oncology therapeutics on the horizon

New oncology therapeutics on the horizon

New oncology therapeutics on the horizon

Veterinary Cancer Society
Veterinary Cancer Society
on behalf of Missouri Veterinary Medical Association


$37.50 $ 37.50 $ 37.50

37.50 $ 37.50 37.50 37.50
Normal Price: FREE $37.50


Launch date: 28 Oct 2015
Expiry Date:

Last updated: 04 Oct 2019

Reference: 161505

TIming: null

Maximum Attendees:

Places Left: 0

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.


New oncology therapeutics on the horizon: The clinical availability of species-specific oncology therapeutics for dogs and cats is rapidly expanding. This session reviews the science and clinical use of several current and future therapeutics for common canine and feline cancers. Discussion will highlight the potential impact these therapies may have on your patients in daily practice.


Learning Objective 1
Become familiar with new veterinary oncology therapeutics which are currently available or will be in the near future with emphasis on:
-Mechanism of action
-Potential clinical uses in dogs and cats with cancer
-Known and potential side effects
Learning Objective 2
Review recent data on more established veterinary oncology therapeutics to aid in best clinical utilization
Learning Objective 3
Understand mechanism and potential role for new oncology supportive therapeutics and how they may positively impact case management and patient quality of life
Veterinary Cancer Society

Author Information Play Video Bio

Veterinary Cancer Society
on behalf of Missouri Veterinary Medical Association

Dr. Chad Johannes, DVM, DACVIM (SAIM, Oncology) is an Assistant Professor of Small Animal Internal Medicine and Oncology at Iowa State University. Having previously practiced in the primary and specialty care settings, his industry experience has included coordination of the launch of Palladia®, the first FDA-approved veterinary cancer therapeutic, and Medical Director at Aratana Therapeutics, Inc. Dr. Johannes’s career has focused on the compassionate care of chronic medical conditions, including cancer, in dogs and cats

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Missouri Veterinary Medical Association
  • 1.00 Hours -
    Exam Attempts: 3
    Exam Pass Rate: 60

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:


User Reviews (0)

Go Back


Saving changes...